CompanyIMRXNasdaqCambridge, MA

Immuneering Corporation

Immuneering develops Deep Cyclic Inhibitors for oncology, including atebimetinib, a MEK inhibitor in late-stage clinical development for RAS/RAF/MAPK-driven cancers.

Stories only

SEC EDGAR ClinicalTrials.gov immuneering.com

10-QAug 5Latest SEC filing, period to Jun 30

Aug 5Latest story

August 2026

Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underway

Aug 5Quarterly updateImmuneering Corporation